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Traditional prophylactic vaccination to prevent illness is the primary objective of many
research activities worldwide.The golden age of vaccination began with an approach called
variolation in ancient China and the evolution of vaccines still continues today with modern
developments such as the production of GardasilTM against HPV and cervical cancer. The
historical aspect of how different forms of vaccination have changed the face of medicine
and communities is important as it dictates our future approaches on both a local and global
scale. From the eradication of smallpox to the use of an experimental vaccine to save a
species, this review will explore these successes in infectious disease vaccination and
also discuss a few significant failures which have hampered our efforts to eradicate certain
diseases. The second part of the review will explore designing a prophylactic vaccine for
the growing global health concern that is allergy. Allergies are an emerging global health
burden. Of particular concern is the rise of food allergies in developed countries where 1
in 10 children is currently affected. The formation of an allergic response results from the
recognition of a foreign component by our immune system that is usually encountered
on a regular basis. This may be a dust-mite or a prawn but this inappropriate immune
response can result in a life-time of food avoidance and lifestyle restrictions. These foreign
components are very similar to antigens derived from infectious pathogens. The question
arises: should the allergy community be focussing on protective measures rather than
ongoing therapeutic interventions to deal with these chronic inflammatory conditions?We
will explore the difficulties and benefits of prophylactic vaccination against various allergens
by means of genetic technology that will dictate how vaccination against allergens could
be utilized in the near future.
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INTRODUCTION
Globally, the burden of disease and infection is diverse and
inescapable. It is a shared affliction for humanity and one that
is constantly moderated by better hygiene, enhanced education,
and improved vaccines and therapeutic interventions. In terms
of healthcare, it is always more beneficial to prevent a disease
or infection from occurring than to treat and cure it. The
development of vaccines is dependent on the knowledge of:
what pathogen causes the disease; how it establishes itself in the
host; how the host’s innate and cell-mediated immunity responds
to pathogens; and how it maintains ongoing protection after
the disease using antibodies. Whilst there are many successful
vaccines currently available, there are still no registered vaccines
for some globally prevalent infectious diseases such as malaria
and human immunodeficiency virus (HIV). Although we have
made enormous progress in medicine over the last 300 years since
the practice of vaccination first began, there are still diseases that
are killing millions of people globally which desperately require
a vaccine. Furthermore, there is a multitude of autoimmune
conditions such as food allergies which may benefit from a
traditional prophylactic vaccination approach. This review will
explore the progression of traditional vaccines from empirical
vaccines to the more recent novel vaccines and how recent
advancements could change the field of allergy research.
A BRIEF HISTORY OF VACCINATION
The first crude attempt at disease control was the procedure of
variolation where the inoculated person stood a good chance at
surviving both the procedure and later exposure to the pathogen.
Variolation consisted of directly transferring the infection from
a sick person to a healthy person, through direct contact or by
infectious matter such as pus, saliva or blood (Dinc and Ulman,
2007). This form of vaccination is believed to have begun in either
ancient China or India, but was only brought to the UK by the
wife of a British diplomat, Lady Wortley-Montagu in 1721 (Dinc
and Ulman, 2007).
Lady Wortley-Montagu had observed that harem girls in
Constantinople had pox-free faces which were attributed to them
being variolated; hence she had her son variolated in Istanbul
in 1718 to save him from experiencing what she had as a young
adult – smallpox. Later she also variolated her daughter in London;
however, this was only after she had confirmed that it did not
www.frontiersin.org July 2014 | Volume 5 | Article 365 | 1
Baird and Lopata The dichotomy of vaccination approaches
result in death or disease in eleven orphans and six convicted
murderers from Newgate Prison (Dinc and Ulman, 2007). Lady
Wortley-Montaguwas so impressed that she imploredher surgeon,
Dr. Charles Maitland, to learn the technique and demonstrate
it to the Royal British Court (Stewart and Devlin, 2006). After
this demonstration, 200 upper-class members of British
society, including members of the royal family, underwent
the procedure, and in 1729 a further 897 more inoculations
were performed with only 17 deaths post-procedure which
is infinitely fewer than smallpox mortality at the time
(Dinc and Ulman, 2007).
Even though Lady Wortley-Montagu was severely criticized
for bringing the procedure to Britain, it was slowly implemented
throughout the UK over the following years, and in 1757 a young
boy named Edward Jenner would be variolated against smallpox
(Dinc and Ulman, 2007). This ultimately saved countless lives
from smallpox; the most devastating disease of the time. However,
there were two issues with variolation: (1) it could impair the
patient or even kill them if the dosage was incorrect or if they
were not physically fit enough to withstand the infection, and
(2) whilst the patient would be protected from further infections,
they would become contagious during the active infection
(Bazin, 2003).
Although variolation was popular in the cities, in the
English countryside there were many rumors that if you
contracted cowpox you were protected from the deadly smallpox.
Subsequently, a farmer named Benjamin Jesty in Yetminster,
England, inoculated his wife and two sons with cowpox in the
hope of surviving a smallpox epidemic (Pead, 2003, 2006). Even
though his wife became very ill, she and the whole family survived
and went on to survive many smallpox epidemics in the area.
This transpired a full 20 years before scientist Jenner began
his experiment with a boy called James Phipps (Pead, 2003);
however, Jesty was recognized for his contribution in 1805 by a
published statement and a portrait commissioned by the Original
Vaccine Pock Institution, London (Pead, 2006). It is believed that
Jenner was also aware of the rumors of cowpox protecting against
smallpox, and that this was the inspiration for his experiment,
resulting in him being the first to document that a person infected
with cowpox would survive subsequent exposure to smallpox
(Stewart and Devlin, 2006). This technique evolved into using
cow inoculums as the vaccine, which did provide immunity to
smallpox although not to the same degree as natural disease or
variolation. This discovery was heralded as the new age of vaccines
and instigated new research into other common diseases.
A couple of centuries later,medicine would againmake another
considerable leap forward with the separate works of scientists
Louis Pasteur and Robert Koch, and the publication of germ
theory. The most famous of these works would be Pasteur’s
and his attenuation of the bacteria Pasteurella multocida, which
causes fowl cholera, by exposing the cultures to air and room
temperature for extended periods of time (Bordenave, 2003).
He demonstrated that whilst the bacteria were avirulent, they
provided full protection from the virulent strain of the bacteria,
which was a revolutionary idea at the time. Pasteur also went on
to attenuate the rabies virus by passage through rabbits (Bazin,
2003). Koch, on the other hand, would discover the bacterial
agents of anthrax, tuberculosis and cholera whilst also compiling
postulates with fellow scientist Jacob Henle that would transform
the world of microbiology (Kaufmann and Schaible, 2005). All
of these discoveries led to the development of immunology and
non-empirical vaccines.
The first whole cell vaccine was produced by Salmon and
Smith in 1886 and was based on a Salmonella strain that was
killed by heat and injected into pigeons to provide immunity
(Bazin, 2003). Around the same time, others were investigating
bacterial components and methods to purify them. This was the
beginning of traditional vaccine methodology. During this era
there weremany great innovations in the field of immunology and
vaccinology, such as the discovery of toxins and the consequent
inactivation of toxins by heat and formalin, killed vaccines,
adjuvants, sub-unit or acellular vaccines, tissue culture and live
attenuated vaccines. With the establishment of molecular biology
and genetic engineering in the late 1950s, a new era began
where vaccine development no longer needed to be empirical and
bacterial components could be produced artificially or even in vivo
by unrelated vectors.
VACCINES IN THE MODERN ERA
What makes a good vaccine?
The traditional definition of a vaccine is one that protects
against a particular (or group of) infectious agent(s); however,
these days there are many vaccines that could be designated
as therapeutic agents against diseases such as cancer (Bergman
et al., 2006), although the goal is still to prevent illness. In
this review we will focus on prophylactic vaccines. The global
market for vaccines is estimated to be around US$8 billion per
year whilst the cost to develop each vaccine from concept to
commercialism is around US$300–800 million (Plotkin, 2005).
The reason for the high expenditure is that each vaccine has to
be rigorously tested before commercial release and the average
time it takes to fully develop a vaccine is between 15 and 20 years
(Arntzen et al., 2005). A successful vaccine is measured by its
effectiveness, its spectrumof protection, the duration of immunity
and the strength of immunological memory that it induces.
Secondary considerations of a good vaccine are its stability, ease
of administration and storage, achievable mass production and its
toxicity.
Biotechnology is a rapidly developing area which allows
continued improvement into the exploration of antigens
suitability as vaccine candidates. Choosing the right antigen is
a core decision in the development of a vaccine candidate as
some antigens that are immunogenic in vivo may not elicit long
term protection. The same antigen may also vary in structure
and sequence between strains, limiting its usefulness. Some
antigens are also hard to express and purify on a large scale
which is required for mass production (Mora et al., 2003). This
is where novel vaccine methodology hopes to improve how
vaccines are made and administered; this will be examined
subsequently.
Routes of administration
The oldest technique for vaccination is that of subcutaneous
delivery via scarification and one of the newest techniques is
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intramuscular injection (Bazin, 2003). Whilst the intramuscular
route of vaccination is quite standard today indeveloped countries,
it is an inconvenient method of application as it requires
sterile needles and syringes, and usually a medical physician
to administer it. This is the major drawback of vaccines that
rely on intramuscular injections to be effective. In one study, a
viral vectored vaccine was found to elicit stronger systemic and
detectable mucosal responses via a single intramuscular injection
than if it was applied via the oral route. The oral route proved
to stimulate suboptimal T-cell responses and did induce a higher
level of mucosal antibody than the intramuscular route (Lin et al.,
2007).
Nasal and oral administration routes of a vaccine are more
desirable than intramuscular as they are non-invasive, painless,
not required to be sterile and do not require a physician for
administration. This final point is most important as it is one
of the reasons that third world countries have the lowest level
of immunizations in the world (Costantino et al., 2007). Nasal
immunization would place the vaccine in contact with the large
surface of the nasal mucosa which consists of the nasal-associated
lymphoid tissue (NALT), which can lead to both humoral and
cellular immune responses (Zuercher et al., 2002; Costantino et al.,
2007). The most well-known nasal vaccine is FluMist®; a live
cold-adapted influenza virus. It can be given as one or two
doses from a syringe sprayer, is licensed for use in the USA
for persons aged 5–50 and has shown high efficacy from its
inception (Plotkin, 2005; Costantino et al., 2007). However, one
of the detriments of a nasal vaccine is that an unpleasant taste
and nasal discomfort can occur often discouraging repeated use
(Atmar et al., 2007).
Oral administration is a practical method of application if
it can be achieved without diminishing the effectiveness of the
vaccine, and immunity can be achieved with a single dose. The
objective of oral vaccines is to mimic a natural infection and
provide mucosal immunity. Orally delivered vaccines can induce
suboptimal T-cell responses with high levels of mucosal antibody
than the intramuscular route; however, the vaccine must be very
stable as it will have to survive the acidic environment of the
stomach before it reaches the M cells of the intestinal wall where
it can be processed by antigen-presenting cells (APCs; Lin et al.,
2007).
Adjuvants
Adjuvants are defined as compounds that influence the immune
system into mounting a Th1 or Th2 response and whilst doing so,
greatly enhances the magnitude of immune response against the
antigen (Marciani, 2003). They are an important aspect of vaccines
due to their tendency to make an ineffective antigen become
effective. It is vital that adjuvants have the following properties:
a non-toxic nature or have minimal toxicity at the dosage to
elicit effective adjuvanticity; able to stimulate a strong humoral
and/or T-cell immune response; provide good immunological
memory or long-term protection; not induce autoimmunity;
are non-mutagenic, non-carcinogenic, non-teratogenic, and
non-pyrogenic; and be stable under broad ranges of storage
time, temperature and pH levels (Marciani, 2003). The most
popular adjuvants are aluminum-based and were first described
and published in 1926 (Glenny et al., 1926). There are three
adjuvants that are currently licensed for human use: aluminum
hydroxide, also known as alum (Davies and Flower, 2007);
monophosphoryl lipid A (MPL) and AS03 consisting of D,L-
alpha-tocopherol (vitamin E), squalene and polysorbate 80 (U.S.
Food and Drug Administration, 2014). It is well established that
aluminum adjuvants stimulate the production of IgE and a Th2
immune profile, yet for some diseases this would not be adequate
protection against pathogens as a Th1 response would be required
(Lindblad, 2004). MPL and AS03 have demonstrated clinical
efficacy when used in a HPV and influenza vaccine, respectively
(Mohan et al., 2013).
Adjuvants are used to lengthen the dissemination time of the
antigen from the site of injection which allows the antigen to be
released over a prolonged period improving the effectiveness of the
vaccine. This feature is called the depot effect and is traditionally
associated with aluminum-based adjuvants (Lindblad, 2004;
Mohan et al., 2013); however, recently the depot effect has been
questioned as reducing the dissemination time of the antigen
does not alter the magnitude of the immune response (Hutchison
et al., 2012) along with other evidence suggesting other modes of
action (reviewed in De De Gregorio et al., 2013). Other methods
in which adjuvants improve the immune response are to form
complexes with the antigen and to target the vaccine towards
specific receptors. For example, the use of mannose in the adjuvant
is recognized by pattern recognition receptors (PRRs) that initiate
endocytosis and antigen processing (Stahl and Ezekowitz, 1998).
The use of pathogen-associated molecular patterns (PAMPs) such
as lipopolysaccharide (LPS) and CpG-DNA, and of synthetic
low-MW imidazoquinolines in adjuvants, all trigger innate
immune responses that lead to a Th1 or Th2 response in the
vaccinated person (Marciani, 2003). Other adjuvants consist of
cytokines (Cheng et al., 2007) and glycolipids (Singh et al., 1999;
Ko et al., 2005) and other immunomodulators (Morrow et al.,
2004) that bind to highly specific receptors on T cells which
activate them.
TRADITIONAL VACCINE METHODOLOGY
The early development of vaccines focused on using killed
organisms, inactivated toxins ormodifiedorganisms, but currently
there are many different approaches to vaccine development,
which will be examined subsequently. As these approaches were
empirical in design, these types of vaccines, whilst being successful,
are now viewed as being traditional vaccines. These can be divided
into three different types: (a) killed vaccines; (b) attenuated
vaccines; and (c) sub-unit vaccines.
Killed vaccines
Akilledor“inactivated”vaccine is developedby thepathogenbeing
grown and then being made inactive by means of heat, chemical
or radiation treatment and was the basis of most vaccines until
the 1980s. This results in the pathogen being unable to cause
disease whilst providing the immune system with stimulation
via its normal antigenic epitopes on its cell surface. One major
disadvantage of this approach is that, whilst these vaccines are
immunogenic, they do not replicate in vivo infectivity limiting the
spectrum of the immunity acquired as the agent is incapable of
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going through its normal antigenic variation over the course of the
infection. This results in decreased immunity and a requirement
of booster shots to maintain immunity (Moylett and Hanson,
2003). Another disadvantage of this vaccine type is that during
the inactivation process the antigenic epitopes can be modified
resulting in a less efficacious vaccine (Tano et al., 2007). Despite
these limitations, killed vaccines are commonly used today with
the typhoid, Salk poliomyelitis, and seasonal influenza vaccines
still being administered (Bazin, 2003; Palese, 2006).
Attenuated vaccines
Among the more efficacious of the traditional vaccines are the
attenuated ones. In this case, a pathogen is subjected to altered
growth conditions, is passage through a host or is genetically
modified to eliminate its virulence, yet retaining its ability to
replicate albeit at a greatly reduced rate. These vaccines are
more successful at eliciting a robust lifelong immunity than other
traditional vaccines. This can be attributed to their ability to cause
an asymptomatic infectionwhich stimulates both the humoral and
cellular branches of the immune system.
However, this ability to replicate carries the greatest risk
as the vaccine can persist in immune-compromised persons
or the elderly due to limited immune responses. A benefit to
these vaccines is they express their own immunogenic antigens
which stimulate the immune system strongly thereby negating
the need for an adjuvant to be used (Loessner et al., 2008). The
most commonly used attenuated vaccine is the MMR vaccine
which protects children worldwide against measles, mumps
and rubella and with subsequent boosters provides lifelong
immunity (Vandermeulen et al., 2007). Attenuated vaccines have
further progressed into carrier vaccines where they can deliver
heterologous antigens (Bachtiar et al., 2003; Lotter et al., 2008;
Schoen et al., 2008). For live carrier vaccines that deliver multiple
heterologous antigens, there is a risk that the host immune system
will dampen the immune response to the heterologous antigens by
misdirecting the immune response against the carrier (Berzofsky
et al., 2004). However, if the immunity induced is cell-mediated
the response can be enhanced by pre-existing immunity to the
carrier strain (Saxena et al., 2013).
Subunit vaccines
Traditionally, it was thought that the only way to protect against
a disease was to use the whole organism to vaccinate the host.
However, it was elucidated that specific parts of the organisms,
when purified or isolated, demonstrated immunogenic properties.
These components could be the capsule, the flagella or even an
outer membrane protein of the cell wall. These types of vaccines
are known as subunit vaccines or acellular vaccines. These vaccines
are not able to cause the disease and in comparison to whole
cell killed vaccines they are not as efficacious. This is both an
advantage as they are safe for immune-compromised patients and
a disadvantage as they do not elicit long-term immunity and
will often require multiple vaccinations to maintain immunity
(Schmitt et al., 2008). An advantage of this type of vaccine is
that it can be engineered to protect against various strains of
the organism. An example of a successful subunit vaccine is the
Haemophilus influenzae type b (HiB) conjugate vaccine which
consists of a polysaccharide-protein conjugate. This vaccine has
eliminated or significantly reduced this disease in children in
regions of South America (Ribeiro et al., 2007; Franco-Paredes
et al., 2008) and Africa (Adegbola et al., 2005; Muganga et al.,
2007) where it was once endemic. In the UK, the success of this
vaccination program was compromised by a highly publicized
paper (which has now been retracted) that linked autism to early
childhood vaccination which lead to a rise in HiB infections
as parents chose not to vaccinate; however, subsequent booster
campaigns by the NHS has seen a reduction in infection rates
again (Ladhani et al., 2008). A recent meta-analysis covering
studies involving over 1.2 million children has discredited any
link between vaccinations or vaccine components thimerosal
or mercury to the development of autism or autism spectrum
disorders (Taylor et al., 2014).
DNA VACCINES – A NEXT GENERATION EXAMPLE
There are multiple novel types of vaccines that are currently under
development, such as bacterial ghosts (Szostak et al., 1996; Jawale
and Lee, 2014) and nanovaccines (Cho et al., 2014). However,
one that holds great promise and has had documented successes
is DNA vaccines. DNA vaccines differ from traditional vaccines
as they do not consist of a protein or a cell component but
only the DNA that encodes an immunogenic antigen within a
plasmid vector. Theplasmid canbe administeredby injection, gene
gun, electroporation, or aerosol delivery, upon which the host’s
immune cells, usually dendritic cells, will sample the plasmid and
express the encoded antigens. These antigens are then degraded
by the cell into peptides and presented via MHC class I and class
II molecules depending on the mode of administration and the
cell type. From this, both antibody and cellular responses can be
induced (Forde, 2005).
The first reported use of a plasmid DNA vaccine outside of
trial or experimental conditions was in 2003 and was a desperate
attempt to save an endangered species from extinction (Bouchie,
2003). The vaccine was for the highly endangered California
condors against the lethal West Nile virus. West Nile virus had
emerged in New York in 1999 and spread to 41 out of the 50
US states killing birds from 138 species in a matter of years. It
was believed that if the virus spread to California, the remaining
200 or so condors would face extinction. The US Centers for
DiseaseControl andPrevention (CDC) expedited themanufacture
of an experimental vaccine and permitted the condors to be
vaccinated with it (Bouchie, 2003). The DNA vaccine expressed
West Nile virus pre-membrane/membrane and envelope proteins.
The vaccinated condors were monitored and it was observed that
the DNA vaccination stimulated protective immunity in adults,
nestlings and newly hatched chicks. Following two intramuscular
vaccinations, the condors demonstrated excellent neutralizing
antibodies 60 days post-vaccination with a continued increase
until approximately 1 year post-vaccination. It was also noted
that the birds did not show any unusual behaviors, health changes
or side effects post-vaccination (Chang et al., 2007). This vaccine
has also demonstrated efficacy in other bird species such as the
American robins (Turdus migratorius) (Kilpatrick et al., 2010) and
the fish crows (Corvus ossifragus; Turell et al., 2003). The first two
DNA vaccines for veterinary use were granted US approval in
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2005 for West Nile virus vaccine for horses and haematopoietic
necrosis vaccine for farm-reared Atlantic salmon (Chalmers,
2006). Even though there are no currently approvedDNA vaccines
for human use, as of May, 2014 there are 128 open trials listed
on Clinicaltrials.Gov (2014) that involve DNA-based vaccines and
therapies
GLOBAL VACCINE SUCCESS
The global eradication of smallpox is, to date; the most successful
vaccination campaign in history. Smallpox has existed for many
thousands of years and spread through the world following the
migration of humans to new settlements (Barquet and Domingo,
1997). As mentioned previously, Edward Jenner is famously
creditedwithdeveloping a smallpox vaccinationusing the cow-pox
virus (vaccinia virus) and published many observations on both
the successful and adverse events (Jenner, 1809) associated with
his vaccination protocol. Small pox was an indiscriminate disease
that is caused by two virus variants Variola major and Variola
minor and was responsible for 300–500 million deaths before its
eradication (Theves et al., 2014). The smallpox vaccine that was
developed by Jenner produces both neutralizing antibodies and
cell mediated responses that are protective against other members
of the Orthopoxvirus genus (Barquet and Domingo, 1997). After
years of vaccination success but with deaths from smallpox still
common, the World Health Assembly, the executive body of
the [World Health Organization (WHO), 2013] set a target to
eradicate smallpox. This was only achievable as humans are the
only reservoir for the virus and the vaccine had demonstrated high
efficacy (Fenner et al., 1988). In the late 1960s, the efforts of the
WHOwere strengthened with more funding and new surveillance
protocols.
The last natural occurrence of smallpox occurred in Somalia,
where cook Ali Maow Maalin developed the rash on October 26th
1977, but tragically it was not the last global smallpox death [World
Health Organization (WHO), 1980]. Medical photographer Janet
Parker became the last person to die of smallpox in the world
when she was accidently exposed to it in her workplace at the
University of Birmingham and unfortunately a lapse in obtaining
her booster vaccination led to her being susceptible at the time of
exposure (Barquet and Domingo, 1997). Eradication of smallpox
was declared on May 8, 1980 by the WHO when the Final Report
of Global Commission for Certification of Smallpox Eradication
was published [World Health Organization (WHO), 1980]. As of
2014, two depositories of smallpox still exist at the CDC in the
USA and the State Research Center of Virology and Biotechnology
VECTOR in Koltsovo, Russia. The destruction of these viral stocks
has been delayed and debated since the declaration of eradication
occurred in, 1980. Discovery of smallpox victims during building
excavations often fuels these debates although no viable virus
has been recovered from these corpses, so the risk of a modern
smallpox outbreak is improbable (Reardon, 2014; Theves et al.,
2014). TheWHO is again debating the existence of these stocks in
May, 2014 (Reardon, 2014).
Another successful vaccine that has been implemented globally
is those against poliomyelitis – the Salk, and Sabin vaccines. There
are three different poliovirus serotypes and all of them can lead to
serious disability in children, even death by acute flaccid paralysis
[World Health Organization (WHO), 2014a]. Due to its moderate
mortality rates, its long-term severe disability consequences and
like smallpox, humans being the only natural reservoir for the
virus, theWorld Health Assembly set a target of eradication by the
year 2000. This project is known as the Global Polio Eradication
Initiative. Poliovirus Type 2 infection has not been observed
since 1999 in India and Type 3 since 2012. However, in 2014,
poliovirus Type 1 is still endemic in regions of Nigeria, Pakistan,
and Afghanistan [World Health Organization (WHO), 2014a].
The reasons behind these persisting endemics will be discussed
later.
There are two vaccines, an oral live attenuated vaccine known
as the Sabin vaccine and the inactivated poliovirus vaccine also
known as the Salk vaccine [World Health Organization (WHO),
2014a]. The Sabin vaccine was derived from passages of the
poliovirus strains through rats and mice and then through cell
cultures more than 50 times resulting in an attenuated forms
of the virus types that all induced good antibody levels (Sabin,
1957; Baicus, 2012). In 1972, Sabin donated his vaccine strains
to the WHO which increased the number of vaccine recipients
from 5 to 80% [Baicus, 2012;World Health Organization (WHO),
2014a]. The Sabin vaccine is no longer in use in the USA or UK
as the only poliomyelitis cases reported in the populations were
vaccine-associated paralytic poliomyelitis where the vaccine strain
has caused an outbreak but it is still used in some developing
countries due to its ease of administration and cost (US$0.14 a
dose vs US$2–3 a dose for Salk vaccine; Willyard, 2014). There
are now plans to eliminate the Sabin vaccine entirely in the 124
countries that still use it by 2015 (Willyard, 2014).
The Salk vaccine is grown in monkey kidney cells and
inactivated with formalin (Salk et al., 1954) and was introduced
in the USA in 1955 and by 1961, the incidence of poliomyelitis
had decreased from 13.9 cases per 100,000 in 1954 to 0.8 cases
per 100,000 in 1961 [Baicus, 2012; World Health Organization
(WHO), 2014a]. Besides preventing deaths, the main benefit
to come from polio vaccination is the cost savings to the
healthcare system which is estimated at US$40–50 billion for
the period between 1988 and 2035 in the USA alone [World
Health Organization (WHO), 2014a]. Most countries that have
been certified polio-free still have rare isolated cases which have
come from travelers importing the virus from endemic areas, for
example in Australia had one such case in 2007 (Paterson and
Durrheim, 2013). However, the Global Polio Eradication Initiative
has a new timeline for eradication and with a new strategy of
phasing out the Sabin vaccines, hopefully theworldwill be certified
polio-free in 2018 (Willyard, 2014).
A more recent vaccine accomplishment is the pneumococcal
conjugate vaccine (PCV) against Streptococcus pneumoniae
(pneumococcus) infections which include acute otitis media,
sinusitis, pneumonia and invasive pneumococcal diseases such
as meningitis and sepsis. The first conjugate vaccine was
a heptavalent vaccine which protects against seven different
serotypes of pneumococcus and it was licensed in the USA
in 2000 (Black et al., 2000; Lee et al., 2014). Since that time,
10- (Domingues et al., 2014), 13- (Spijkerman et al., 2013), and
23-valent (Grabenstein and Manoff, 2012) vaccines have been
licensed with all producing strong immunity against a broad
www.frontiersin.org July 2014 | Volume 5 | Article 365 | 5
Baird and Lopata The dichotomy of vaccination approaches
spectrum of strains. In the USA, all age groups from children
under 5 years to adults over 65 years had dramatic reductions in
incidence of pneumococcal infections over a seven year period
after the PCV was available (Pilishvili et al., 2010).
It is predicted that if the heptavalent PCV was implemented
in China it would prevent 4222 cases of invasive pneumococcal
disease, 4,061,524 cases of otitis media and 472,527 cases of
pneumonia, as well as preventing an additional 2682 deaths
from pneumococcal disease; however, the implementation cost
would be estimated at US$6.44 billion (Che et al., 2014). The
current overall cost of pneumococcal disease in the unvaccinated
population in China is estimated to be US$3.5 billion (Che et al.,
2014). Following the introductionof PCV in theUSA,an estimated
211,000 serious pneumococcal infections and 13,000 deaths were
prevented in the period of 2000–2008 (Pilishvili et al., 2010). The
influence of this vaccine on public health is in its early stages and
has alreadyhad impacts on childmortality in over 88 countries that
have included various PCV on their recommended immunization
schedule (Whitney et al., 2014).
There are other vaccines that have been successfully
implemented in the past decade. The most recent and highly
publicized vaccine is the quadrivalent human papillomavirus
vaccine against cervical cancer, marketed as Gardasil®, which
prevents the premalignant disease that leads to cervical cancers
and fulfills all the above criteria of being a successful vaccine
(Zhou et al., 1991; Govan, 2008). Initially the cost of Gardasil®
was extremely prohibitive at US$120 per dose with three doses
required; however, in collaboration with GAVI Alliance, the
cost from the supplier has dropped to US4.50 per dose which
increases its affordability and likelihood of being implemented in
developing countries (Anon, 2013). As the cost of the vaccine
decreases and more people are immunized this vaccine which
has been included in over 30 countries immunization schedules,
in conjunction with regular Pap screening, may lead to a long-
term reduction in cervical cancer incidence (Harper et al., 2010;
Ribeiro-Muller and Muller, 2014).
VACCINE FAILURES AND CHALLENGES
Historically there have been more vaccine failures than successes
and unfortunately those failures can be publicized and instill
fear in the general public long after the event. One such failure
is one that occurred early in the rollout of the Salk polio
vaccine is known as the Cutter incident. In April, 1955 a few
weeks after Salk’s polio vaccine had been declared safe and
efficacious, there were reports from California that five children
had become paralyzed after receiving the vaccine (Offit, 2005).
These vaccines were traced to Cutter which was one of the
five pharmaceutical companies that were granted a license to
produce the vaccine in the USA (Nathanson and Langmuir,
1995). It was found that two production batches failed the
deactivation steps; so live virulent poliovirus was found in
120,000 doses of the vaccine. Of the children vaccinated from
this pool, 40,000 developed abortive polio, 51 suffered from
permanent paralysis and five died (Nathanson and Langmuir,
1995). Unfortunately this was not the end of the tragedy, a polio
outbreak followed where a further 113 people in close contact
with the vaccinated children were infected and subsequently
paralyzed, and a further five deaths (Nathanson and Langmuir,
1995; Offit, 2005). This incident halted the implementation of
the polio vaccine program and severely affected public confidence
in the vaccination, not only in the USA but as far reaching
as New Zealand (Day, 2009), Germany, the UK and Sweden
(Axelsson, 2012) and in the end, it caused the USA to recommend
Sabin’s vaccine in the long term which, barring manufacturing
failures, proved to be the more risky of the two vaccines
as it could revert to full virulence and cause outbreaks of
vaccine-associated paralytic poliomyelitis (Offit, 2005; Fitzpatrick,
2006).
Following its emergence in 1981, HIV infections and its
subsequent disease acquired immunodeficiency syndrome (AIDS)
has become a global pandemic with millions of deaths and over
34millionpeople livingwithHIV (DeCock et al., 2012). According
to the [World Health Organization (WHO, 2014c) ] and the Joint
United Nations Programme on Hiv/Aids (2013) the pandemic
appears to have peaked as AIDS-related deaths have decreased by
25% in the past decade as well as new infections decreasing by 20%
since 2006. This is the combined effect of the development of anti-
retroviral drugs, and better education about the transmission of
this disease. However, a vaccine is desperately needed to prevent
new infections and to stop this pandemic from affecting future
generations.
Multiple HIV vaccines have been tested in clinical trials with
limited success (Johnson et al., 2013). In the last decade, the
most prominent vaccine trial failures was that of the Merck STEP
phase II test of concept and efficacy trial for an Adenovirus5
(Ad5) vaccine. It showed that the MRKAd5 HIV-1 gag/pol/nef
vaccine was highly immunogenic and elicited a higher magnitude
of HIV-specific CD8+ T cells than any of the other HIV candidate
vaccines over the past 15 years but it did not prevent HIV
infection or reduce viral loads in infected patients (Buchbinder
et al., 2008). In fact, more disturbingly, there was an increase
in the number of HIV-1 infections in male recipients of the
vaccine compared to the controls (McElrath et al., 2008). This
trial was immediately ceased when the independent data and
safety monitoring board determined that the study could not
demonstrate efficacy (Buchbinder et al., 2008).
One of the reasons behind the failure of theMerck STEP clinical
trial was the pre-existing neutralizing antibodies against Ad5. A
recent study confirmed that the international epidemiology of
pre-existing immunity to different adenovirus types can severely
compromise its efficacy as only 14.8% of the 1904 participants
were seronegative for neutralizing antibodies against Ad5 (Mast
et al., 2010). This indicates that naturally acquired infections from
virulent forms of the vaccine vectors can limit their usefulness
in the same species. However, choosing a virus from a different
species for which no prior exposure is possible but may sound
too risky to be accepted by the general population. It was also
found that whilst the group of men that became more susceptible
to HIV infection post-vaccination were seropositive against the
Ad5 vector, they were also uncircumcised and had sexual relations
with the same sex implying that pre-existing immunity may not
be the sole factor that caused this vaccine failure (Gray et al., 2010;
Duerr et al., 2012). Whilst this phase II trial failure was a major
setback for the HIV research community, it raised fundamental
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questions about the pathogenesis of HIV and also gave insight
into immunological mechanisms that were previously unexplored
(Johnson et al., 2013; Fauci et al., 2014). The search for a HIV
vaccine is ongoing and as of May 2014, there are 92 open HIV
vaccine trials according to Clinicaltrials.Gov (2014).
Another infectious disease that is under surveillance by health
departments worldwide is a double-stranded RNA virus called
rotavirus. Rotavirus causes acute enteritis resulting in severe,
dehydrating diarrhea in infants and young children and is very
transmissible through close contact [Bishop et al., 1976; World
Health Organization (WHO), 2013]. In the pre-vaccination era,
rotavirus caused 111 million cases of illness with 25 million
medical visits, 2 million hospitalizations and between 352,000
and 592,000 rotavirus gastroenteritis-associated deaths worldwide
annually with most of these occurring in low income countries
(Parashar et al., 2003). The first rotavirus vaccine was RotaShield
which was developed by Wyeth-Lederle Vaccines and Pediatrics,
Philadelphia, as an oral vaccine and showed high efficacy at 80%
protection from severe illness; hence it was recommended for all
infants in the USA once it was approved by the Food and Drug
Administration (FDA) on August 31, 1998 (American Academy of
Pediatrics, 1998). Over the eleven month period after the vaccine
was approved until July 7, 1999, 15 cases of intussusception, a
type of intestinal blockage requiring surgical intervention, were
reported and linked to the vaccination. In consultation with
the FDA, Wyeth-Lederle Vaccines withdrew Rotashield from the
market on October 15, 1999. Before this withdrawal, the cases of
confirmed intussusception had risen to 101 (Delage, 2000) and
fortuitously, because there were no deaths caused by this vaccine,
physician trust in vaccine safety measures were not compromised
by this withdrawal (McPhillips et al., 2001).
In 2006, two new oral rotavirus vaccines were released onto the
market: Rotarix® – a live monovalent attenuated human strain by
GlaxoSmithKline Biologicals (Vesikari et al., 2004; Keating, 2006b)
and RotaTeq® – a live pentavalent human-bovine reassortant
vaccine by Merck & Co. Inc. (Clark et al., 2004; Keating, 2006a).
After 6 years of use, a Cochrane Review found that both of
these vaccines are efficacious with no increased risk of adverse
side effects such as intussusception (Soares-Weiser et al., 2012).
However, in 2013, a small increase in risk was confirmed when
the data was analyzed comparing the risk of intussusception in the
post-vaccine period with other periods (Haber et al., 2013; Quinn
et al., 2014).
A year later, the vaccines are still on the market albeit with
an intussusception warning even though there is an estimated
up to sixfold increase with the use of these two rotavirus
vaccines. So far the Vaccine Safety Datalink has reported that
Rotarix® has had 66 intussusception cases in 200,000 doses, whilst
RotaTeq® had eight cases for 1.3 million doses administered
with most occurring within 7 days after the first dose [World
Health Organization (WHO), 2014b]. Currently the risk of
intussusception is estimated to be 1–2 per 100,000 infants
vaccinated [World Health Organization (WHO), 2013]. However,
the general view is that there are great benefits to vaccination
against rotavirus as the infant mortality rates in countries that
have added this to their vaccination schedule have significantly
decreased (Buttery et al., 2014) and this is reflected in the WHO’s
Global Advisory Committee on Vaccine Safety in their weekly
epidemiological record [World Health Organization (WHO),
2014b] stated this in regards to the new intussusception risk:
“the findings remain reassuring that the risk of intussusception
following current rotavirus vaccines remains small compared
to the benefits of preventing the impact of severe diarrhea.”
Surveillance of such adverse effects requires long-term study in
order to make sound decisions about the appropriateness of the
vaccine. There may come a time where the relative risk is too
high and the vaccine is withdrawn like Rotashield which had a
rate of intussusception of 1 in 10,000 infant doses [World Health
Organization (WHO), 2013], even though it provided strong
immunological protection. This is one of the hardest aspects in
vaccine development to plan for and may lead to public distrust
in future vaccines, if it is not done expediently when those risks
increases.
POLITICAL AND GLOBAL ASPECTS OF VACCINE USAGE
When a vaccine is designed, it is assumed that if it proves effective
it will be used in various countries around the world to vaccinate
the population; however, this is not always the case. Within each
country there are government agencies, industry and community
health advocates, and outside agencies such as the WHO that
will make recommendations for vaccination strategies. Often this
process will result in a successful vaccination strategy such as the
global eradication of smallpox (Stewart and Devlin, 2006), but it
can also lead to confusion and scepticism in the chosen strategy.
One such examplewas the choice of pertussis vaccine for a national
vaccination campaign in the Netherlands.
Originally, the Dutch government chose to use a whole cell
vaccine based on the Bordetella pertussis bacterium; however,
after speculation that the vaccine could cause brain damage,
alternative vaccines were sought. At this time, acellular vaccines
comprising three to five bacterial components were being used
by many countries in Europe as they were comparable in
protection to the whole cell vaccines and demonstrated minimal
side effects (Blume and Zanders, 2006). Over the course of
7 years, the debate over the new vaccine became very convoluted
as many government agencies, drug companies, and consumer
groups presented opposing studies and evidence. There was also
external pressure from neighboring countries and global non-
profit groups including the WHO and United Nations Children’s
Fund (UNICEF) for the Dutch government to make a decision.
Concurrently, many parents had lost faith in the old vaccine
strategy; hence an epidemic of pertussis ensued. To combat
the growing epidemic the Dutch government chose an acellular
vaccine which was used in primary vaccinations in 2005; however,
the Health Minister advised that this decision was not based on
recommendations and evidence provided by the Dutch Health
Council, but on the need to appease parents and re-establish
their confidence in the vaccine strategy (Blume and Zanders,
2006). By contrast, in areas where any disease is endemic and
the health system is overwhelmed, often the vaccination strategy
proposed by governing bodies will be accepted by the population
and acquiesced as mandatory (Chalmers, 2006).
Unfortunately this has not worked in areas such as Pakistan,
Nigeria, and Afghanistan where the eradication of polio has failed
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due in part to misinformation, violence, politics, and mistrust
about vaccination. There is a distinct divide in these populations
between vaccine acceptors and non-acceptors which is based in the
abundance of misinformation about the vaccine, religious beliefs
and the emotional fear about the agenda; however, if there is an
outbreak many non-acceptors will accept the vaccination as the
fear of disease outweighs the perceived risks (Murele et al., 2014).
Socio-cultural, educational and perceptual factors are particularly
strong in these regions and in some cases targeting male authority
figures could improve vaccination uptake (Murele et al., 2014);
however, in other regions maternal education and empowerment
has been suggested as a strong motivator in vaccine acceptance
(Larson et al., 2014).
Violence is another contributing factor to this program’s
failure particularly when there are fatal attacks on vaccination
workers in Pakistan and Nigeria (Abimbola et al., 2013). In
Afghanistan, both the Taliban regime and the militant Islamist
terrorist group Al Qaeda support the Global Polio Eradication
Initiative; however, factions within these groups can disrupt it
as they view it as a Westernization issue, rather than a health
one (Abimbola et al., 2013). In Nigeria and Pakistan, militants
can gain international media attention by attacking polio health
workers (Riaz and Rehman, 2013) and spreading propaganda
that immunization programs are actually covert sterilization
campaigns to reduce the Muslim population, which puts more
fear into the local communities than the disease itself (Abimbola
et al., 2013; Willyard, 2014).
All of the aforementioned issues affect the successful
eradication of infectious diseases with well documented
epidemiology and pathology. However, there exist conditions and
disorders where the mechanisms of development and ongoing
chronic pathology are yet to be fully ascertained. One such
condition causing concern among health professionals globally
is allergy.
ALLERGY AND VACCINE POTENTIAL
Allergy is a hypersensitivity disease characterized by the
production of IgE antibodies against antigenic components (i.e.,
allergens) that can enter the body via the respiratory and
gastrointestinal tract, the skin, an insect sting or injection of
a drug (Sicherer and Sampson, 2014). The clinical reactions
experienced by sensitized patients vary in different target organs
and include rhinitis, urticaria, and allergic asthma to life-
threatening anaphylactic shock (Sampson, 2003, 2004). The acute
symptoms of allergy are usually due to the release of inflammatory
mediators by tissue-bound mast cells and circulation basophils.
These inflammatory mediators include histamine, platelet-
activating factor, leukotrienes, mast cell proteases, and a range
of cytokines. Mediators are released when allergen binds to IgE
antibody attached to FεRI receptors on the cell surface, causing
degranulation. Studies show a skewing towards a Th2 response,
with elevated levels of IL-4, IL-5, and IL-13, while tolerant
individuals usually have higher levels of the Th1 cytokines IFN-
gamma and TNF-alpha, and the regulatory cytokine IL-10 (Andre
et al., 1996; Noma et al., 1996; Schade et al., 2003; Turcanu et al.,
2003; Tiemessen et al., 2004). The class switch to produce IgE
antibody occurs during primary sensitization in allergic patients
and seems to be driven by IL-4, which is a direct product
of Th2 cells and other effector cells of the allergic immune
response. The activation of allergen-specific T cells is achieved
by the presentation of allergens via APCs, including dendritic cells
(Grainger et al., 2014; Nagai et al., 2014).
As the prevalence and potential fatality of this disease
has increased, so have the efforts to find effective therapies
and prophylaxis also intensified (Valenta et al., 2010). Specific
immunotherapy (SIT) is effective for desensitization against
inhalant allergens; however, it is not advised as a therapy against
food allergy because of the high risk of adverse side-effects (Sabato
et al., 2014). Oral administration of antigens usually leads to
tolerance, and has been effective in decreasing allergic sensitization
to antibiotics and other medications (Stevenson, 2000, 2003).
Obviously native food allergens cannot be administered in
this way, but it may be possible for hypoallergenic or CpG-
conjugated derivatives. Microencapsulation provides a promising
way of delivering allergens without degradation in the stomach
(Litwin et al., 1996), thereby inducing oral tolerance, and
has already been applied in clinical trials (TePas et al., 2004).
Conjugation or co-administration of recombinant allergens with
Th1-inducing heat-killed bacteria has yielded good protective
results in mice (Li et al., 2003a,b) and allergic dogs (Frick et al.,
2005). Various approaches have been attempted to develop safe
and effective DNA vaccines and are discussed in the following
section.
DNA VACCINES AND ALLERGY
DNA vaccines, as demonstrated in the California condors, can
induce protective immune responses against infectious diseases.
Plasmid DNA injected intramuscularly, intraperitoneally or with
a gene gun results in transcription and translation of encoded
genes and elicits an antibody response in the host (Tang et al.,
1992; Ulmer et al., 1993; Hsu et al., 1996b). This method of
immunization preferentially induces a Th1 immune response and
suppression of IgE (Raz et al., 1996; Yoshida et al., 2000). These
effects appear to bemediated by both CD8+ and CD4+ cells (Hsu
et al., 1996a; Lee et al., 1997; Peng et al., 2002), and plasmid DNA
requires immunostimulatory sequences such as CpG for optimal
immunogenicity (Sato et al., 1996; Adel-Patient et al., 2001; Jilek
et al., 2001; Hartl et al., 2004). Unmethylated CpG motifs either in
bacterial DNA or as synthetic oligodeoxynucleotides (CpG-ODN)
are recognized by the mammalian immune system via toll-like
receptor 9 (and possibly other PRRs) and trigger a Th1 response
(Hartmann and Krieg, 1999; Stacey et al., 2000; Bauer et al., 2001).
Experiments in murine models of allergic asthma, rhino sinusitis,
and conjunctivitis show that administration of CpG-ODN alone
prevents symptoms and reduces already established disease by
reducing Th2 immune responses and IgE (Kline et al., 1998,
1999; Magone et al., 2000; Serebrisky et al., 2000). Allergen/CpG-
ODN conjugates have been shown to be less allergenic and more
immunogenic thannative allergen (Tighe et al., 2000;Horner et al.,
2002). The major allergen from ragweed, Amb a 1, linked to
an immunostimulatory DNA sequence promoted Th1 cytokine
expression and down regulated Th2 expression in vitro (Simons
et al., 2004), reversed established airway hyperreactivity in a
murinemodel of asthma (Marshall et al., 2001; Santeliz et al., 2002)
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and yielded promising results in Phase II clinical trials (Tulic et al.,
2004).
Genetic immunization to specific allergens using plasmid DNA
offers a powerful solution to the major problems associated with
protein immunization, such as cross-linking of IgE antibody on
effector cells or even de novo synthesis of IgE antibodies to the
immunized protein itself. However, genetic vaccination may lead
to an uncontrolled synthesis of allergens in the vaccinated host
(Slater et al., 1998) and has been a major hurdle for application in
allergic patients. Three approaches are currently used to prevent
this from occurring: (a) cutting the allergen-coding gene into
fragments, lacking the antigenic determinant but containing the
original T cell epitope repertoire, (b) the use of hypoallergenic
protein derivatives, or (c) fusing allergen with proteins that
promote immune responses.
Several allergens have been tested in DNA vaccination
approaches using murine models, including Ara h 2 (peanut),
bovine beta-lactoglobulin (cow’s milk), Cry j 1 (Japanese
cedar), phospholipase A2 (bee venom), Der f 11 and Der p 1
(dust-mite), and Bet v 1 and Phl p 2 (grass; Roy et al.,
1999; Toda et al., 2000; Adel-Patient et al., 2001; Jilek et al., 2001;
Kwon et al., 2001; Peng et al., 2002; Hochreiter et al., 2003;
Ludwig-Portugall et al., 2004). Most studies observed elicitation of
a Th1 response and increased IL-10 production. Mice vaccinated
against phospholipase A2 were protected against fatal anaphylaxis
following allergen challenge (Jilek et al., 2001), while mice
receiving an oral DNA vaccine containing the peanut allergen
Ara h 2 (Roy et al., 1999) experienced significantly less severe
and delayed allergic reactions upon subsequent sensitization and
challenge. However, prophylactic effects, while promising, are not
sufficient to aid patients who have existing food allergy. In mice
pre-sensitized to phospholipase A (bee venom), therapeutic gene
vaccination prevented only 30% of mice from anaphylaxis (Jilek
et al., 2001).
In addition to direct DNA vaccination, these approaches
provide the option of co-delivering genes or adjuvant molecules
with immunomodulatory properties together with the antigen
sequence (Hartl et al., 2004; Mutschlechner et al., 2009). Allergen–
allergen hybrid molecules may combine different allergens from
one complex allergen source or use allergens fromdifferent sources
as demonstrated for grass pollen (Linhart et al., 2005;Wallner et al.,
2009). Furthermore, hybrid molecules using only T cell epitopes
have been successfully used (Linhart et al., 2008). Vaccination
of mice with a plasmid containing the cDNA for OVA fused to
the cDNA of IL-18 (Allergen–cytokine fusion protein), a potent
Th1 inducer, reversed established airway hyperreactivity, while
a plasmid containing OVA alone had only a prophylactic effect
(Maecker et al., 2001).
Ubiquitination of allergens represents another routine
approach for destroying IgE-binding epitopes on proteins to
produce hypoallergenic DNA vaccines. This approach has been
applied for the production of a DNA-based vaccine encoding an
ubiquitinated version of Linhart v 1, themajor allergen from birch
pollen (Bauer et al., 2006). It was demonstrated in a murine study
that this vaccine did not produce any detectable antibody response,
but T cell reactivity was preserved as well as allergic reactions
prevented.
In summary, several novel therapeutic and prophylactic
therapies against allergy are currently under investigation
(Nieuwenhuizen and Lopata, 2005; Flicker et al., 2013;Weiss et al.,
2013). Genetic immunization has proven a powerful method to
induce anti-allergic immune responses. The underlying functional
principle described seems to be based on the recruitment of
allergen-specific Th1 cells, CD8+ cells and the establishment
of a Th1 cytokine milieu. This response can be protective by
preventing the development of a Th2-biased response towards
allergens, as well as balance an ongoing Th2-type response in a
more therapeutic application. More studies are needed to increase
our understanding of the pathophysiology and immunological
mechanisms of allergy, and to characterize themolecular structure
and epitopes of allergens, to develop safer and more effective
ways of combating this debilitating andpotentially life-threatening
disease.
CONCLUSION
The advent of vaccination changed global society and our everyday
lives dramatically, especially in conjunction with improved
healthcare, infrastructure and technology. Over the last century
with increasing knowledge of the immune system and infectious
diseases, infant mortality associated with infectious diseases
dropped, in developed countries debilitating illnesses like polio
disappeared from public view, and the youth of today did not
experience the threat or fear of death via infectious diseases.
However, some diseases such as HIV and malaria are yet to have
efficacious vaccines developed and successfully complete Phase
III clinical trials. So the fight continues against these known
enemies and with each failure, we learn more. The list of global
health threats consists of many incurable infectious diseases;
immunological disorders such as allergy should be added to that
list. Currently, therapeutic interventions are adequate, but with
population and allergy prevalence increasing there is a strong need
for a prophylactic vaccine. Although the establishment of allergy
is not fully elucidated, researchers should be mining the already
long history of infectious disease vaccines to create new avenues
of allergen vaccine development.
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